Skip to content

Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging

Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07640568
Acronym
PARENT-EAR
Enrollment
40
Registered
2026-06-10
Start date
2026-09-01
Completion date
2027-08-31
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Otitis Media, Otitis Media

Keywords

acute otitis media, otitis media, digital otoscopy, telemedicine

Brief summary

Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise. Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children. The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization. Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant). Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent. Intervention group: Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed. Control group: Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice. Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation. This is a pilot study with a target sample size of 20 children per arm, limited by device availability. Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest. The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis. Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata. All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.

Interventions

DEVICEAssigning of a digital otoscope to the families in the intervention group

Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.

Sponsors

Turku University Hospital
Lead SponsorOTHER_GOV
Vaasa Central Hospital, Vaasa, Finland
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Months to 47 Months
Healthy volunteers
Yes

Inclusion criteria

* At least one episode of AOM within the last 12 months * Family speaks fluent Finnish

Exclusion criteria

* Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy * Middle ear fluid at the time of recruitment * Previously diagnosed hearing loss * Immunosuppressive disorder or medication, excluding inhaled corticosteroids * Anatomic defect or anomaly affecting the susceptibility to AOM * Previous otoscopy experience of the participating parent

Design outcomes

Primary

MeasureTime frameDescription
Number of physician visits due to suspected AOM5 to 9 months, depending on date of recruitmentNumber of physician visits due to suspected AOM

Secondary

MeasureTime frameDescription
Agreement between parent interpretation, AI classifier, and expert gold standard5 to 9 months, depending on date of recruitmentParent's interpretation of the tympanic membrane image is retrospectively compared to the expert's gold standard and classification by an artificial intelligence classifier
Antibiotic prescription rates5 to 9 months, depending on date of recruitmentAntibiotic prescription rates for AOM in both arms
Adverse events related to otoscopy5 to 9 months, depending on date of recruitmentAdverse events, such as abrasion, related to otoscopy in the experimental group
AOM-related complications5 to 9 months, depending on date of recruitmentAOM-related complications, such as mastoiditis, in both arms
Daycare absence5 to 9 months, depending on date of recruitmentChild's absence from daycare due to suspected AOM
Parental work absenteeism5 to 9 months, depending on date of recruitmentParental work absenteeism due to suspected AOM
Parental satisfaction on a visual analog scale (VAS)5 to 9 months, depending on date of recruitmentParental satisfaction in the experimental group of AOM management with parent-led digital otoscopy

Countries

Finland

Contacts

CONTACTSimo Nuuttila, MD
simo.c.nuuttila@utu.fi+358503314426
CONTACTPaula A Tähtinen, MD, PhD
paula.tahtinen@utu.fi+35823130000
PRINCIPAL_INVESTIGATORPaula A Tähtinen, MD, PhD

Department of Paediatiatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026